人附睾蛋白4在卵巢癌早期诊断及预后监测中的应用进展

卵巢癌是常见的妇科恶性肿瘤,早期无症状,一旦诊断多属晚期,病死率居妇科恶性肿瘤之首。因此,针对卵巢癌的高危因素做到早期诊断并采取一定的阻断措施,必将减少部分卵巢癌的发生与死亡。人附睾蛋白4是新近提出的肿瘤标志物,在卵巢肿瘤组织高表达,在癌旁组织不表达,特异性较CA125高,与卵巢癌的组织类型、分期、分级等存在相关性,在血液、尿液中均可检测到,对卵巢癌的早期诊断、复发和预后的监测有良好的辅助诊断效果。

The Progress of HE4 in the Application for Early Diagnosis and Prognosis Monitoring of Ovarian Cancer

Ovarian cancer is a common gynecological malignancy derived from epithelial tissue,which is asymptom in the early stage,once diagnosed,mostly are in the late stage,therefore the mortality is at the top among the gynecological tumors.Therefore,early diagnosis of ovarian cancer risk factors and taking some of the blocking measures is bound to reduce the incidence and mortality of ovarian cancer.Human epididymis protein 4(HE4) is a recently proposed tumor marker,which has high expression in ovarian tumor tissue,without expression in cancer adjacent tissues.HE4 has higher specificity than CA125,and is related to histological types of ovarian cancer,stages,grades,etc..It could be detected not only in the blood,but also urine,which has a good auxiliary diagnosis effect for the early diagnosis and monitoring of recurrence and prognosis.